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Abstract
Background: The Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
item library covers a wide range of symptoms relevant to oncology care. There is a need to select a subset of items relevant to
specific patient populations to enable the implementation of PRO-CTCAE–based symptom monitoring in clinical practice.
Objective: The aim of this study is to develop a PRO-CTCAE–based subset relevant to patients with lung cancer that can be
used for monitoring during multidisciplinary clinical practice.
Methods: The PRO-CTCAE–based subset for patients with lung cancer was generated using a mixed methods approach based
on the European Organization for Research and Treatment of Cancer guidelines for developing questionnaires, comprising a
literature review and semistructured interviews with both patients with lung cancer and health care practitioners (HCPs). Both
patients and HCPs were queried on the relevance and impact of all PRO-CTCAE items. The results were summarized, and after
a final round of expert review, a selection of clinically relevant items for patients with lung cancer was made.
Results: A heterogeneous group of patients with lung cancer (n=25) from different treatment modalities and HCPs (n=22)
participated in the study. A final list of eight relevant PRO-CTCAE items was created: decreased appetite, cough, shortness of
breath, fatigue, constipation, nausea, sadness, and pain (general).
Conclusions: On the basis of the literature and both professional and patient input, a subset of PRO-CTCAE items has been
identified for use in patients with lung cancer in clinical practice. Future work is needed to confirm the validity and effectiveness
of this PRO-CTCAE–based lung cancer subset internationally and in real-world clinical practice settings.
(JMIR Cancer 2021;7(3):e26574) doi: 10.2196/26574
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Introduction
Background
Lung cancer is the most common cancer in men and the third
most common cancer in women worldwide [1]. Treatment
options are often multidisciplinary, including surgery,
chemotherapy, radiation therapy, targeted therapy,
immunotherapy, or a combination of these treatments [2]. Owing
to both the tumor and the (combination of) treatments, patients
can experience a wide range of symptoms and toxicities that
impair their health-related quality of life (HRQoL) and require
careful management [3]. Historically, toxicities have been rated
by health care practitioners (HCPs) most typically using the
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Common Terminology Criteria for Adverse Events (CTCAE),
which is broadly implemented to monitor toxicity in oncology
trials and clinical care [4]. The concept of clinician scoring has
recently been challenged by a number of studies that have
observed relatively high levels of disagreement between
toxicities reported by clinicians and patients [5-7].
Patient-reported outcome measures (PROMs) have been
demonstrated to improve patient-clinician communication about
symptoms and are therefore increasingly recognized as an
important source of information in clinical decision-making
[8-10]. PROMs could also function as a tool for routine toxicity
management as part of clinical care. In two previous randomized
trials, Basch et al [11] and Denis et al [12] used a selection of
patient-reported symptoms to monitor symptoms during
chemotherapy in patients with metastatic cancer and lung cancer,
respectively. These trials have shown that PROM symptom
monitoring not only improves symptom management but also
significantly improves HRQoL and overall survival [11-14].
Potential underlying mechanisms for these positive results
include an earlier and therefore more effective response to
progressively evolving symptoms, including timely initiation
of supportive treatments, dose modifications, and early referrals
[11,12,15,16].
On the basis of the results of these trials, there has been a
growing call for the development and implementation of
standardized patient-reported symptom monitoring tools for use
in both clinical research and clinical practice [14,17]. A major
advance in this direction has been the development and testing
of the US National Cancer Institute’s Patient-Reported Outcome
Version of the CTCAE (PRO-CTCAE). The PRO-CTCAE is
developed through a consortium of patient-reported outcome
(PRO) researchers, clinical investigators, trial sponsors, patient
advocates, and the Food and Drug Administration (FDA), and
it comprises 124 items, based on 78 CTCAE toxicities
considered appropriate for patient reporting [18]. These items
have been comprehensively validated in English-speaking
patients [19] and have been translated and linguistically
validated in a large number of languages, including Dutch [20].
Frequent administration of the complete library of PRO-CTCAE
items is considered impractical and burdensome [18,21].
However, this validated item library of symptoms can form the
basis of a PRO monitoring subset. Conforming to what the FDA
has described, the selection of a relevant item set is of critical
importance to provide insights into the most important toxicities
for the treatments that are being evaluated [22]. Several studies
have focused on creating a subset of PRO-CTCAE. Examples
include an item subset for patients with bladder cancer receiving
chemotherapy and immunotherapy, and a subset of patients
receiving immunotherapy in metastatic melanoma [23-25].
Similar to most cancer diagnoses, lung cancer is often treated
in a multidisciplinary setting, including a treatment plan for
multiple modalities and a variety of involved health care
professionals [26]. These multidisciplinary teams can use
PROMs to improve the collective monitoring of patients [27].
Objective
The aim of this study is to systematically develop a
multidisciplinary subset of PRO-CTCAE items that are clinically
relevant for patients with lung cancer and that can be used for
monitoring during multidisciplinary clinical practice.
Methods
Item Identification
A schematic overview of the subset identification method is
presented in Figure 1. The original PRO-CTCAE item library
was the main source and starting point for the development of
the lung cancer subset. The procedure to identify relevant items
for the subset approximates phase 1 of the European
Organization for Research and Treatment of Cancer (EORTC)
Quality of Life Group guidelines for developing PROMs [28].
Three sources were used to compile the relevant item list.
Figure 1. A schematic overview of the item identification process. HCP: health care practitioner; PRO-CTCAE: Patient-Reported Outcomes Version
of the Common Terminology Criteria for Adverse Events.
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First, a literature search was conducted to ensure the
identification of all relevant toxicities from both the literature
and existing questionnaires. We used the PubMed database,
with the following search terms: non-small cell lung
cancerORsmall cell lung cancer AND adverse events OR
toxicities OR symptoms OR side effects AND Chemotherapy
OR Radiation OR Chemo radiation OR Immunotherapy OR
targeted therapy OR surgery. From these results, the literature
that included existing questionnaires and reviews on lung cancer
toxicity was selected. Next, we identified the PRO-CTCAE
items that corresponded to the symptoms derived from the
literature. The literature study was conducted as comparative
evidence to be used complementary to the data collected from
the patients and HCPs.
Second, the patients’ perspectives were included to ensure
content validity [29]. A heterogeneous sample (n=25) of patients
with lung cancer was invited to participate in a semistructured
interview. Patients were recruited from the Netherlands Cancer
Institute. We used purposive sampling to include patients
varying in terms of age, sex, stage, and treatment type. The
eligibility criteria were as follows: aged ≥18 years; able to
provide informed consent; either currently undergoing lung
cancer treatment (at least 2 weeks after the start of treatment)
or in follow-up (having completed lung cancer treatment within
the previous 6 months); and basic fluency in the Dutch language.
The exclusion criteria were psychological or cognitive problems
as judged by the HCP, which would interfere with participating
in an interview.
Finally, the HCPs working in the Netherlands Cancer Institute
(n=22) in the field of lung cancer, including pulmonologists
(n=4), radiation oncologists (n=12), thoracic surgeons (n=3),
and nurse specialists or physician assistants (n=3) specialized
in the treatment of lung cancer, were invited for an interview
to provide their opinions about the most relevant items to be
included in a lung cancer subset.
Interview Procedures
A scripted interview guide was used based on the EORTC
guidelines [28]. During the first part of the interview, patients
were asked to freely describe their experiences and symptoms.
Subsequently, patients were asked to complete the PRO-CTCAE
item library by filling out a questionnaire that included all items.
This was followed by a debriefing interview to determine what
the experienced symptoms meant to the patient, the extent to
which patients had experienced the symptoms, and if they had
experienced any symptoms not included in the questionnaire.
Patients were encouraged to comment on the PRO-CTCAE
symptom terms and were asked to rate each symptom for
relevance using a scale of 1 (not relevant) to 4 (very relevant)
[28]. Patients were asked to select a maximum of 10 most
impactful symptoms to assess the importance of the
PRO-CTCAE symptoms. Finally, patients were asked to identify
symptoms that should definitely be included or excluded.
The HCPs took part in a semistructured interview in which they
were shown the complete PRO-CTCAE item list and were asked
if (1) there were symptoms included that the medical specialists
considered clinically relevant (scored as 1) or irrelevant (scored
as 2; in terms of treatability and urgency) for patients with lung
cancer and (2) if symptoms were missing from the list that they
considered relevant. The reasons for relevance or irrelevance
were specified.
Item Selection
An overview table was created based on the complete
PRO-CTCAE item library, in which the results of the data
collection were collected and ranked. For literature data, the
prevalence of the item in the included literature sources was
calculated (literature score). Next, for patient data, the mean
relevance score for each PRO-CTCAE item was calculated
(patient relevance score). The top 10 items (based on the patient
relevance score) were reviewed and compared to gain insight
into the different treatment modalities. Finally, for the HCP
data, the percentage of HCPs who rated it as relevant was
calculated (HCP relevance score). The table was then sorted
from high to low using the patient relevance score data as the
primary rank, followed by the HCP relevance score and the
literature score.
For the final item selection, the ranked list of items was
reviewed by an expert review panel, including a pulmonologist,
a radiation oncologist, an epidemiologist, and two public health
experts. During this process, the relevance scores of the patients
were of primary importance in the selection of items. The expert
review consisted of three rounds. First, all items with a low
patient relevance score (<2) were reviewed. Next, items with a
high patient relevance score (>2.5) were reviewed. The third
round consisted of a review of items with a relevance score
between 2 and 2.5. Decisions to include or exclude items from
the final list were based on the following features: (1) lack of
clinical relevance (in terms of treatability and urgency), (2)
upsetting items, and (3) redundancy (multiple closely related
items) [28]. As the goal was to generate a subset of items most
relevant for clinical practice without creating excessive
respondent burden, the item that was indicated most relevant
by the patients was chosen in case of redundancy (eg, fatigue
and insomnia). The discussions continued until a consensus was
reached over the final item selection.
Results
The Literature
Table 1 provides an overview of the selected studies. Relevant
literature included the following existing questionnaires: the
EORTC Quality of Life core questionnaire (QLQ) C30 and the
EORTC QLQ Lung Cancer module (EORTC QLQ LC13), the
Development of the Functional Assessment of Cancer
Therapy-Lung, and the MD Anderson Symptom Inventory for
lung cancer [30-33]. More recent efforts to define relevant
patient outcomes in lung cancer by Mak et al [34], Reeve et al
[35], and Koller et al [36] were included as well. From the study
by Koller et al [36], we included a list of quality of life issues
as rated by patients and HCPs in phase 1 of the EORTC Module
Development Guidelines [28].
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Table 1. The Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events items that were identified in the literature
for each included source.
StudyPRO-CTCAEa item



























aPRO-CTCAE: Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events.
bDevelopment of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life core questionnaire (QLQ) C30 and the
EORTC QLQ Lung Cancer module (EORTC QLQ LC13).
cDevelopment of the Functional Assessment of Cancer Therapy-Lung.
dDevelopment of MD Anderson Symptom Inventory for lung cancer.
eBased on the phase 1 study of the international study to revise the European Organization for Research and Treatment of Cancer questionnaire for
assessing quality of life in lung cancer patients.
fDelphi study with health care professionals in the field of lung cancer.
gSystematic literature review and expert panel.
hItem present.
The following 24 PRO-CTCAE items were identified from the
selected literature: fatigue, shortness of breath, decreased
appetite, pain, dizziness, constipation, insomnia, nausea, sad
or discouraged, difficulty swallowing, anxious, hoarseness,
vomiting, numbness and tingling, concentration, voice quality
changes, hair loss, memory, rash, decreased libido, acne, nail
loss, nail ridging, and nail discoloration.
Patient Interviews
Table 2 presents an overview of the patients and treatment
characteristics. The mean age of the patients was 66 years (SD
8). The stage distribution was as follows: stage I, 8% (2/25);
stage II, 12% (3/25); stage III, 36% (9/25); and stage IV, 44%
(11/25). A broad range of treatment modalities (radiotherapy,
3/25, 12%; stereotactic radiotherapy, 2/25, 8%; concurrent
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chemotherapy and radiation, 5/25, 20%; surgery, 5/25, 20%;
and systemic treatment such as chemotherapy, 1/25, 4%;
immunotherapy, 6/25, 24%; and targeted therapy, 3/25, 12%)
were included.





66 (8; 55-79)Age (years), mean (SD; range)














Treatment status, n (%)
14 (56)On treatment
9 (36)<1 month posttreatment
2 (8)1-3 months posttreatment
Highest level of education, n (%)
3 (12)Primary school
2 (8)Lower vocational education
9 (36)High school
6 (24)Higher vocational education
5 (20)Scientific education
Fatigue was scored as the most relevant symptom from the
patient’s perspective, with a patient relevance score of 85.7.
Seven other items were scored above 2.5 (shortness of breath,
cough, insomnia, decreased appetite, dizziness, constipation,
nausea, and sadness).
When reviewing the items per treatment modality, the top 10
items per modality category (radiotherapy, systemic treatment,
concurrent chemoradiation, and surgery) were compared.
Fatigue, shortness of breath, and cough overlapped in all
modalities, and dizziness, hives, and constipation overlapped
in three out of four modalities. Some items were present in two
of the four categories, including sadness for systemic therapy
and surgery, itchy skin and joint pain for both radiotherapy and
surgery, and insomnia in concurrent radiation and surgery.
Although most items overlapped between categories, the
different treatment modalities seemed to influence the type of
symptoms that were described as most relevant by the patients.
Radiotherapy-specific symptoms included taste changes, dry
skin, headache, and bruises. The concurrent
chemoradiation-specific symptoms were urinary frequency,
heart palpitations, and difficulty swallowing. Items specifically
relevant for systemic treatment (ie, chemotherapy,
immunotherapy, and targeted therapy) were discouraged,
anxiety, and nausea. Finally, patients treated with surgery
described flatulence and achieve and maintain an erection.
HCP Interviews
The participating HCPs reported having experience with a
variety of treatment modalities. They had experience with
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chemoradiation 77% (17/22), immunotherapy 23% (5/22),
surgery 18% (4/22), radiotherapy 59% (13/22), chemotherapy
18% (4/22), and experimental or targeted therapies 9% (2/22).
Of the participating HCPs, 36 items had an HCP relevance score
<50%. The items that were identified as most relevant by the
HCPs included shortness of breath, wheezing, fatigue, decreased
appetite, nausea, difficulty with swallowing, vomiting, and
headache.
Item Selection
All PRO-CTCAE items were ranked by patient relevance score
first followed by HCP relevance score and finally literature
score, which is shown in Multimedia Appendix 1. An overview
of the item selection process is shown in the flowchart in Figure
2. In round 1, 46 items were excluded. These items had a low
patient relevance score of <2. The expert panel collectively
agreed to eliminate these items. In round 2, items with a high
patient relevance score of >2.5 were discussed for inclusion.
This list consisted of eight items, including fatigue, shortness
of breath, cough, insomnia, decreased appetite, dizziness,
constipation, and sadness. Experts agreed to include all these
items with the exception of insomnia and dizziness. The item
fatigue was chosen over insomnia because fatigue covers more
than insomnia, and these items are known to be highly
correlated. Furthermore, fatigue was scored more frequently
across all data sources than insomnia (patients, HCPs, and the
literature). There was no expert consensus on the inclusion of
dizziness based on clinical relevance. Moreover, this item scored
relatively low on the HCP relevance score and the literature
score compared with the other items in round 2 and was
therefore not included.
In round 3, 23 items with a patient relevance score between 2
and 2.5 were discussed. Uniform agreement for exclusion of
the following items was reached: urinary urgency, decreased
libido, body odor, itchy skin, flatulence, concentration, increased
sweating, achievement and maintenance of erection, urinary
frequency, and dry skin. The remaining items were discussed
by the expert panel. Of these items, nausea was ranked the
highest with a patient relevance score of 2.42, an HCP relevance
score of 71.4, and a literature score of 50. On the basis of these
scores and the judgment of clinical relevance, the expert panel
decided to include this item in the final list. The item taste
changes and difficulty swallowing were excluded because of
their correlation with the higher-ranked item decreased appetite.
The item rash was excluded because of the low level of clinical
relevance based on the expert panel, as well as the low literature
score (12.5). The item joint pain had a higher patient relevance
score than the item for general pain (2.33 and 2.29,
respectively). However, in light of the clinical use of the
questionnaire, the item general pain was preferred because it
would cover more than solely joint pain and was therefore
included in the list. The items discouraged and anxious were
excluded because the higher ranking and the correlating item
sadness was already included. The item wheezing was excluded
because the higher ranking and correlation item shortness of
breath was already included in round 2.
Therefore, the final list of eight items included fatigue, cough,
shortness of breath, decreased appetite, constipation, nausea,
general pain, and sadness.
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To our knowledge, this is the first study to develop a
PRO-CTCAE–based subset for the PRO-based monitoring of
toxicity in patients with lung cancer. This subset enables the
incorporation of patient perspectives in clinical monitoring of
patients with lung cancer using the well-established and
FDA-endorsed PRO-CTCAE item library. This study may serve
as an example for the future development of other site-specific
PRO-CTCAE–based subsets for symptom monitoring in clinical
practice.
Previously, there have been successful efforts of PRO-based
monitoring in several trials showing improved symptom
management, HRQoL, and even overall survival [11-14]. Basch
et al [11] performed a trial (n=766) testing PRO-based
monitoring in patients treated with chemotherapy for advanced
solid tumors. This trial used a list of 12 common symptoms
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based on previous literature [37]. Denis et al [38] performed a
similar PRO-based monitoring trial in patients with lung cancer
(n=121). Both author groups did not report on the development
of the symptoms list, but they performed a study on the
capability of symptom lists to detect lung cancer relapse [38].
When comparing our final item list with the lists used by Denis
et al [38] and Basch et al [11], our study results seem to be fairly
consistent with the symptom lists used in these successful
PRO-based monitoring trials. In total, 50% (4/8) of items are
listed in both lists, that is, cough, shortness of breath, decreased
appetite, pain, and fatigue (Denis et al [38] used weakness)
[14,17]. Two items, constipation and nausea, were only listed
by Basch et al [17]. Finally, sadness was not a part of the two
PRO-based monitoring trials. Sadness and depression are
however closely related and often sadness may indicate an
occurrence or development of depression [14,17]. Items that
were not included in our list because they were not included in
the PRO-CTCAE item library were fever, facial swelling, lump
under the skin, voice changes coughing up blood, and body
weight. Other items that did not correspond with our subset
were painful urination, diarrhea, hot flashes, and tingling, which
were included in the more heterogeneous trial of Basch et al
[17].
The study results are also in line with previous efforts of creating
a symptom subset. A recent study created anatomic site-specific
PRO-CTCAE item sets, including items for thorax radiation
[39]. Their results were based on 30 patients who received
thoracic radiation (including 16 patients with lung cancer). Their
proposed relevant item set is in line with the results of this study
[39]. Few previous studies have systematically selected a subset
of PRO-CTCAE items [23,25]. Nissen et al [25] specifically
aimed at three types of drugs and their adverse events in the
treatment of metastatic prostate cancer, which were mainly
based on FDA, European Medicine Agency, and randomized
controlled trial reports and included relatively small samples
of patients’ interviews (n=16). This resulted in a relatively large
subset of 25 PRO-CTCAE items compared with this study.
Even though the number of items tested by Nissen et al [25]
was considered feasible, they were tested in a setting of a
one-time measurement only. Therefore, the presented subset
might be a more feasible choice for weekly monitoring over a
longer period. Moreover, the length of the subset was also
comparable with the questionnaires used in previous successful
trials that performed weekly monitoring [11,14]. Furthermore,
this study, along with other studies, was performed in different
target populations with slightly different aims, for example,
Tolstrup et al [24] focused on immunotherapy in metastatic
melanoma, and the study by Taarnhøj et al [23] focused on
chemo- and immunotherapy for bladder cancer, whereas in this
study, it was a requirement from our sponsor of Dutch medical
specialists involved in the treatment of patients with lung cancer
to have the same questionnaire for the (often) multimodality
lung cancer treatment.
Strengths and Limitations
The key strength of this study is the use of a mixed method
approach that includes the literature, patients, and expert
perspectives. This study included a patient sample that reflected
the stage distribution of the lung cancer population and included
a variety of treatment modalities that are frequently used in
clinical practice [40]. This multidisciplinary subset allows the
monitoring of patient symptoms during the entire treatment
course and therefore facilitates implementation within clinical
care settings [41]. The emphasis on the patient and expert
perspective may facilitate the implementation of PROMs within
clinical cancer care, so the chance that this subset is perceived
as valuable to the clinician is more likely to enable successful
clinical implementation [16].
Our subset is a valuable PRO tool because it enables reliable
remote monitoring, which can help provide necessary care to
patients while minimizing the use of health care facilities.
Remote monitoring using directly integrated PROM results in
the electronic health record is expected to be successful because
it minimizes barriers for use within the daily clinical routine
[42].
The findings of this study are subject to several limitations. A
methodological choice to let patients rate the items on a scale
of 1 to 4, as opposed to the binary HCP rating that was used in
this study, might have influenced the comparability of both
results. However, we believe the 1 to 4 scale gives the patients
a tool to rate the relative importance of their own experience,
where an HCP can judge relevance or irrelevance based on a
large number of cases and expertise.
For this subset, a set of items that were intended as a core set
for multidisciplinary use were selected. Despite the advantages
of multidisciplinary use and implementation, one could argue
that the treatment experience may vary based on the different
treatment modalities, and this could cause symptoms to be
missed in patients depending on the specific treatment that is
given. The results of this study showed that some symptoms
were experienced as specifically relevant for distinct treatment
modalities. One may consider adding these treatment-specific
items when the subset is solely used in the context of one
treatment modality. Moreover, we encouraged the use of the
PRO-CTCAE’s other symptoms item, in which a patient can
freely report and score additional symptoms.
An arguable weakness that needs to be considered when
interpreting these findings is that this study was designed as an
EORTC phase 1 or 2 study to develop guidelines for developing
PROMs (hence the relatively small sample). This entails that
in order to make statements with regard to psychometric
properties, acceptability, and compliance, further international
field testing is needed. This study was a single-center study,
and multicenter verification is certainly needed. Nonetheless,
the PRO-CTCAE item library has proven to be a valid and
reliable questionnaire in previous studies, and it has only
recently been linguistically validated in Dutch-speaking patients
[19,20]. Moreover, the PRO-CTCAE subset with the additional
items of body weight and temperature and a specification of
coughing up blood is currently being tested in the trial
SYMPRO-Lung (Symptom Monitoring With Patient-Reported
Outcomes Using a Web Application Among Lung Cancer
Patients in the Netherlands; Netherlands Trial Register:
NL7897).
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This study presents a subset of PRO-CTCAE items for
multidisciplinary PRO monitoring of patients with lung cancer
during and after treatment. The results of the final item selection
were considered relevant for monitoring patients with lung
cancer. Continued efforts are needed to further validate the
psychometric properties and the value of the PRO-CTCAE lung
cancer subset in real-world clinical practice.
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